Literature DB >> 8558145

Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease.

G Giovannoni1, J W Thorpe, D Kidd, B E Kendall, I F Moseley, A J Thompson, G Keir, D H Miller, M Feldmann, E J Thompson.   

Abstract

OBJECTIVE: To determine whether concentrations of soluble E-selectin (sE-selectin), an immunological marker of endothelial activation, were correlated with gadolinium-DPTA enhancement on MRI in patients with multiple sclerosis.
METHODS: Serial sE-selectin concentrations were measured in 28 patients with multiple sclerosis undergoing monthly gadolinium (Gd) enhanced MRI of the brain and spinal cord, and in 10 control subjects. C reactive protein (CRP), von Willebrand factor (vWF), and tumour necrosis factor-alpha (TNF alpha) were also determined.
RESULTS: Primary progressive patients had significantly increased sE-selectin concentrations compared with the relapsing remitting and secondary progressive patients who had normal sE-selectin concentrations (22.2 (SD1 6.1) ng/ml v 9.8 (SD2.1) ng/ml and 7.7 (SD2.7) ng/ml, respectively, P = 0.03). This difference was attributable to five of the 10 primary progressive patients who had persistently raised sE-selectin concentrations, with relatively inactive MRI studies. No correlation could be found between sE-selectin concentrations and Gd enhancement on MRI, but a close correlation existed between mean concentrations of sE-selectin and TNF alpha (r = 0.71, P < 0.001). Despite raised sE-selectin and TNF alpha concentrations, primary progressive patients had normal CRP concentrations (1.03 (SD1.14) mg/l), which were significantly lower than the relapsing remitting (3.16 (SD2.54) mg/l) and secondary progressive patients (2.28 (SD2.1) mg/l, P = 0.03). Raised CRP concentrations did correlate with infectious episodes, clinical relapse, and Gd enhancement, and were significantly raised when no MRI activity was found. Concentrations of vWF were normal in all patient groups.
CONCLUSIONS: The results further high-light the differences between patients with primary progressive and those with relapsing remitting/secondary progressive multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558145      PMCID: PMC486184          DOI: 10.1136/jnnp.60.1.20

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  38 in total

1.  Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view.

Authors:  H F Cserr; P M Knopf
Journal:  Immunol Today       Date:  1992-12

2.  Effects of tumour necrosis factor and interleukin-1 on von Willebrand factor secretion from human vascular endothelial cells.

Authors:  E M Paleolog; M A Carew; J D Pearson
Journal:  Int J Radiat Biol       Date:  1991 Jul-Aug       Impact factor: 2.694

Review 3.  Endothelial-leukocyte adhesion molecules.

Authors:  M P Bevilacqua
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

4.  Oligodendrocyte injury is an early event in lesions of multiple sclerosis.

Authors:  M Rodriguez; B W Scheithauer; G Forbes; P J Kelly
Journal:  Mayo Clin Proc       Date:  1993-07       Impact factor: 7.616

5.  The attraction of adhesion molecules.

Authors:  J P Antel; T Owens
Journal:  Ann Neurol       Date:  1993-08       Impact factor: 10.422

6.  Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells.

Authors:  J R Gamble; Y Khew-Goodall; M A Vadas
Journal:  J Immunol       Date:  1993-05-15       Impact factor: 5.422

7.  An immunogenetic heterogeneity in multiple sclerosis.

Authors:  J Hillert; M Grönning; H Nyland; H Link; O Olerup
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

8.  E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro.

Authors:  J F Leeuwenberg; E F Smeets; J J Neefjes; M A Shaffer; T Cinek; T M Jeunhomme; T J Ahern; W A Buurman
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

9.  Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis.

Authors:  M K Sharief; R Hentges
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

10.  Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-alpha concentrations.

Authors:  P Riches; R Gooding; B C Millar; A W Rowbottom
Journal:  J Immunol Methods       Date:  1992-08-30       Impact factor: 2.303

View more
  10 in total

Review 1.  Mechanisms of dendritic cell trafficking across the blood-brain barrier.

Authors:  Divya Sagar; Catherine Foss; Rasha El Baz; Martin G Pomper; Zafar K Khan; Pooja Jain
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-06       Impact factor: 4.147

2.  1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Authors:  J Suhy; W D Rooney; D E Goodkin; A A Capizzano; B J Soher; A A Maudsley; E Waubant; P B Andersson; M W Weiner
Journal:  Mult Scler       Date:  2000-06       Impact factor: 6.312

3.  Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.

Authors:  G V McDonnell; S A Hawkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

4.  Inflammatory profile, age of onset, and the MTHFR polymorphism in patients with multiple sclerosis.

Authors:  Sudabeh Alatab; Arash Hossein-nezhad; Khadijeh Mirzaei; Fatemeh Mokhtari; Gholamreza Shariati; Azam Najmafshar
Journal:  J Mol Neurosci       Date:  2010-12-29       Impact factor: 3.444

5.  Peripheral blood mononuclear cell membrane fluidity and disease outcome in patients with multiple sclerosis.

Authors:  Gloudina M Hon; Mogamat S Hassan; Susan J van Rensburg; Stefan Abel; Rajiv T Erasmus; Tandi Matsha
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-21       Impact factor: 0.900

6.  Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.

Authors:  Kaarina Kowalec; Kyla A McKay; Scott B Patten; John D Fisk; Charity Evans; Helen Tremlett; Ruth Ann Marrie
Journal:  Neurology       Date:  2017-11-08       Impact factor: 9.910

7.  Red blood cell membrane fluidity in the etiology of multiple sclerosis.

Authors:  Gloudina M Hon; Mogamat S Hassan; Susan J van Rensburg; Stefan Abel; Paul van Jaarsveld; Rajiv T Erasmus; Tandi Matsha
Journal:  J Membr Biol       Date:  2009-11-14       Impact factor: 1.843

Review 8.  Coagulation Pathways in Neurological Diseases: Multiple Sclerosis.

Authors:  Nicole Ziliotto; Francesco Bernardi; Dejan Jakimovski; Robert Zivadinov
Journal:  Front Neurol       Date:  2019-04-24       Impact factor: 4.003

9.  Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions.

Authors:  Chen Cheng; Ying Jiang; Xiaohong Chen; Yongqiang Dai; Zhuang Kang; Zhengqi Lu; Fuhua Peng; Xueqiang Hu
Journal:  BMC Neurol       Date:  2013-07-03       Impact factor: 2.474

10.  Mucosal Administration of E-selectin Limits Disability in Models of Multiple Sclerosis.

Authors:  Jacqueline A Quandt; Pierre Becquart; Emily Kamma; John Hallenbeck
Journal:  Front Mol Neurosci       Date:  2019-08-27       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.